Surgical Innovations Share Discussion Threads

[gbh2] 25/9/2018 13:11

Holding RNSs are rare here.

[bashor] 25/9/2018 13:09

So it now seems like someone managed to sell quite a chunk at 3.4p hopefully the overhang is cleared

[buywell3] 24/9/2018 15:18

What long term

The cost for cancer drugs per MONTH is more than a once in a lifetime Bariatric MIS operation at around $7000


6.500 € / 5.700 £ (gastric bypass)
5.300 € / 4.200 £ (gastric banding)
6.500 € / 5.700 £ (gastric sleeve)
5.000 € / 4.000 £ (gastric plication)




Cancer drugs costs have DOUBLED in ten years to $10,000 per MONTH.




The DoH should act and save taxpayers monies

[meijiman] 24/9/2018 10:23

Sounds as though a detailed cost benefit analysis could help make the case for surgery then ie the rise of cancer related issues linked to obesity costs more in the long term.

[buywell3] 24/9/2018 09:45

The NHS have been trying that approach for years

Weight loss on the cheap.

It does not work

Which is why the NHS and many other Health Services are in the financial plight they are.

They are not prepared at present to spend circa £7k on a patient for an intervention weight loss operation once .... to save the present cost £107k per year for many types of cancer drugs.

[meijiman] 24/9/2018 08:46

why not eat less and eat healthily rather than having to undergo surgery for weight loss?

[buywell3] 24/9/2018 07:52

Obesity is making the headlines most weeks now ...

Health services worldwide must start to take new preventative actions ASAP to intervene in obesity growth by bariatric keyhole surgery.



SUN have products that fit this need




The new application for Fix8 by Advanced Medical Solutions ( made by SUN ) is directly aimed at providing a solution to this Obesity Epidemic with the gastric sleeve surgery application

Note the phrase

''Clinical work is ongoing to broaden the claims to include other laparoscopic surgical applications,''

So more applications to come for Fix8.



LiquiBand® Fix8™



The design modifications for LiquiBand® Fix8™, our hernia mesh fixation device were completed in the first quarter of 2018, and the new version is now being fully promoted. Surgeon feedback has been extremely positive, and we recorded our highest level of quarterly sales for this product in Q2 2018 resulting in H1 2018 sales increasing by 16% at reported and constant currency to £1.0 million (2017 H1 £0.8 million). Clinical work is ongoing to broaden the claims to include other laparoscopic surgical applications, such as gastric sleeve surgery.



At present, the laparoscopic device is approved for use in Europe and those markets that accept European approval standards. We have begun the US approval process which is expected to take another two years and to cost approximately £3 million as it will necessitate a full set of clinical trials. These are expected to start early next year, once we obtain the Investigational Device Exemption with the FDA.



Development of the open surgery hernia mesh fixation device is close to completion and EU approval for this product is expected this year.



We continue to be excited for the long term prospects for LiquiBand® Fix8™.






Obesity to eclipse smoking as biggest cause of cancer in UK women by 2043

[bashor] 20/9/2018 21:38

It does look like a buy order is being filled at 3.4p still doesn’t explain today’s drop though

[jmf69] 20/9/2018 20:41

Sells going through above the mid price this afternoon at 3.32. Also a delayed 500k buy showing up

[srichardson8] 19/9/2018 18:59

for the record I see two 1.1mn share trades shown at different times after hours at 3.4p - that is about 640k. It may be the same trade, it may not, but it smells of institutional buying. No trades within market hours today.

[srichardson8] 18/9/2018 14:38

11-9-19 Surgical Innovations SUN at Balls Bros Old Broad Street
Presenting: Nigel Rogers Executive Chairman, Melanie Ross COO CFO
Nuts & bolts
The factory N of Leeds is 30/-ft2 with 70 staff. Output could be doubled from this facility. Sales are centred in Hungerford, Berkshire at Elemental. Total staffing around 100.
The £5mn fund raising was notable for the £2mn investment by Ruffer, usually regarded as a long-term investor
The Walbrook site has a useful outline of the company with the investment summary section including some earning estimates.

Interims
These were unaudited half-year results to June but please note the change in year end to March effective in the current reporting period.
The UK distribution company Elemental was acquired in August 2017. Net of the Elemental contribution revenues were broadly flat and net debt unchanged. A simple general point was that inventories fell by £0.5mn and that capex requirements in this period and going forward are modest.
3 Divisions
Segmental -SI Brand
revs +13.1% - mostly reflecting additional contribution from throughput of SUN products at Elemental. Some pick-up in NHS activity following problems early in the year from lack of hospital beds and its effect on operating schedules, notably producing delays in elective surgery. The US business fell sharply, -25%, reportedly on de-stocking but also price pressures. The company is trying to get additional lines handled by Elemental into N America. A concern.
Europe was flat, RoW boosted by assuming direct contact with the Japanese distributor. Japan rose 76%. This was formerly effeted via a Getz (13% shareholder) subsidiary with the parent approving the change. This has helped considerably but the main benefit was from the introduction to this market of the upgraded Elite range.
There are 2 or 3 new products ‘in the pipeline’, including an optical trocar (
Segmental - OEM is split into two segments
a) Traditional OEM supplies notably a device for Advanced Medical Solutions Fix-8 – a major product, now re-designed, used in hernia procedures
b) Precision engineering (‘PE’) – has been boosted by a project with a 3rd party company still in the test stage
Segmental
The spike in precision engineering revenues (H1 revs £400k) reflected a collaboration with the aerospace industry still at the testing stage. This is presumably the RR effect discussed elsewhere in this blog.
Microline – an extension to the agreement until Q1 2021 with this US reposable company, a subsidiary of Hoya of Japan
Meccelis – (see recent news confirming transition to new certification) – M. is a French company but the UK market is significant with the most important area breast reconstruction. I won’t parrot the explanation but crudely the pre-pectoral method, in which cellis is used, may have significant advantages over alternatives. The company expects shipments to show up in revenues from the October quarter. Elemental is distributing a US product from Invuity (recently bought by Stryker) which improves visibility.

Questions
Competition? Advanced Medical and others – mostly disposable products often from China or Mexico based on dollar prices. SUN own products are largely ‘resposable’, the razor blade model.
R&D? £1mn p.a., about half capitalised and offset against a similar figure for amortisation. 3 development engineers, 5 production engineers.
Dependency on the NHS? 95% of UK sales are to the NHS so perhaps half of total sales. Supplying about ¼ of all NHS hospitals.
Where are SI group products used? All basically between the waist and the neck. Gastro Intestinal, breast.
Is some remuneration solely in share awards? No, this practice for the Executive Chair and Non-exec Directors has been replaced by mostly cash remuneration

Tentative Conclusions
Good impression of Mr Rogers and Ms Ross. Board singing from same sheet.
Pick-up from H2 helped by re-certification of cellis products

[buywell3] 18/9/2018 11:35

advfn have P/E at 33.50 with following numbers

Turnover 8.75 Profit 0.54
Norm EPS 0.10 PE Ratio 33.50 Market cap 26.22


I think this full year will be around 11.6M turnover thanks to recent good news RNS and AMS sales lift of Fix8

I think 2019 has every chance of turnover £13M and profits of £1.5M

Forward P/E of 11

With AMS getting another Application Approval for Fix8 and more new products due soon
This is very doable IMO


SUN have just stated

• Positive outlook for H2 & beyond

• Activity level ramping up in Q3 to meet increasing demand

Segmental – OEM

• Progress

• Fix-8 re-design completed in H1

• Phase III project in PE segment
completed and moved to pilot
production

• Anticipate strong H2


Board looking forward with confidence

[bashor] 17/9/2018 21:36

The time to buy in I’d say, the ducks are lined up now for 2019

[lurki0] 17/9/2018 20:02

srichardson8 - yes please. It would be immensely helpful.

[srichardson8] 17/9/2018 19:47

Yes but there was a management presentation in London last week at Balls Bros in Old Broad Street. I went and was left with a pretty good impression. I will give a few facts or impressions when I have some time. But in principal a buyer.

[jmf69] 17/9/2018 15:43

The presentation is on the company website

[srichardson8] 17/9/2018 14:08

there was a presentation in London last week. Has anyone commented or summarised?

[mandate] 17/9/2018 13:00

@buywell3 thanks for the posts

[buywell3] 17/9/2018 12:42

.... OBESITY is now the BIGGEST Health threat in the Western World .....


Look at it another way , combating Obesity by the provision of new surgical products, services and surgical equipment is becoming a GROWTH Industry.

So it is good to see SUN introducing more products via its Elemental Healthcare arm to sell to use in Obesity reduction operations , also good to see AMS planning to use Fix8 to do the same in their new application for its use.


Thus for SUN ... Investors should and probably many do , see Surgical Innovations as a green type investment in as much as what it makes and sells helps humanity.


The Obesity epidemic is crippling the NHS financially as well as causing over 50% of the worst diseases ie Diabetes , Stoke and heart conditions , various forms of cancers. All of these can be long term conditions for patients costing £ Billions a year in expensive drug provisions.


But they can be prevented by early intervention surgery to reduce obesity BEFORE it triggers other conditions.

Professor Roger Williams: The big fat truth about obesity? It costs us £40bn a year- and is crippling our NHS




In 2015

The Centers for Disease Control and Prevention (CDC) estimates that 110,000 Americans die as a result of obesity each year, and that one-third of all cancers are directly related to excess weight.

Data collected from over 60,000 Canadians also shows that obesity now leads to more doctor visits than smoking. One in four Americans is also pre-diabetic or diabetic, and heart disease and cancer—both of which are associated with obesity—top the mortality charts.

According to Christopher Murray,1 one of the authors of a comprehensive new analysis2, 3 published in The Lancet,4 all this excess body weight causes an estimated 3.4 million deaths worldwide each year. As noted by Bloomberg



Obesity rates in 2018 are up since then and showing now signs of slowing

[buywell3] 17/9/2018 11:37

Just in case anyone has any doubts about SUN working with RR re above post



page 13

• R&D collaboration with Rolls Royce to develop a laser deployment mechanism


also




and note this guy worked for SUN before becoming a lead RR design engineer




Lead Design Engineer
Rolls-Royce
September 2017 – Present 1 year 1 month
Derby, United Kingdom
The role involves managing the design lifecycle of gas turbine rotating components (discs, shafts, drums and blisks) NPI and modifications from design concept to implementation.

Project Leader - Design and Development Engineer
Surgical Innovations Ltd
May 2016 – July 2017 1 year 3 months
Leeds, United Kingdom
Role includes leading medical device development projects medical device concept generation; engineering analysis and detail design; design of experiments; design for high and low volume manufacturing; working to Quality Management Systems such as ISO 13485 and 21CFR820; risk management to ISO14971; change management; Design History File compilation; verification and validation.

[buywell3] 17/9/2018 11:20

Possible adoption worldwide for the whole Aviation industry if RR make it a success






17 Jul 2018

“We are in the process of developing a number of miniature devices that enable us to get inside the jet engine to perform inspections or repairs,” Dr. James Kell, on wing technology specialist at Rolls-Royce, told Digital Trends.

“Repairs can be in the form of removing damaged material or putting material back on. To allow us to perform these repairs, we are working with an extensive network of partners to develop mechatronic probes — similar in nature to keyhole surgery techniques.”

The idea is that the snake-inspired robot could gain access to an engine in the manner of an endoscope, the long, thin flexible tube inserted by doctors into a patient’s body to view it from the inside.

It could then deliver a swarm of tiny, miniature robots, of around 10mm in diameter, which can crawl around inside the engine.




Been a long time coming , but now the mini robots are here

Keyhole surgery on wing ready for take-off Graham Bowland Published: 08:51 Thursday 23 May 2013


SURGICAL Innovations is to use its pioneering keyhole surgery techniques to examine jet engines without having to take them apart. The group is looking at other industrial areas following a new funding deal with its long-standing industrial partner, thought to be Rolls Royce.

The Leeds-based group said the funding will be used to develop a bespoke solution to allow jet engines to be inspected while they are still on the wing. At the moment engines have to be completely taken apart and stripped off in order to carry out routine maintenance or fix a problem. Discover the new king of the spy thriller ‘London Rules takes the Jackson Lamb series to new levels of nerve-shredding tension, leavened as always with moments of eye-watering hilarity - ...

Sponsored by John Murray Surgical’s chief executive, Graham Bowland, said: “Our keyhole surgery flexible technology enables us to go into restricted areas, whether they are restricted by space, heat or radiation. It helps to reach places where you can’t go.

“We can find a pathway through and get an instrument through – be it a probe, a screwdriver or a bolt cutter. It’s incredibly clever technology. “It proves that the technology we’ve been working on works. We can do keyhole surgery on the wing.” Surgical’s design engineers have developed a unique pathway into the engine that winds its way down like a snake and delivers an instrument that examines that part of the engine. “We don’t make probes and screwdrivers. We provide the delivery mechanism.

It’s keyhole surgery on jet engines,” said Mr Bowland. Surgical is currently looking at other industrial areas where it can apply its keyhole surgery techniques. “We are looking at any area of industry where a human can’t go because they are prohibited by space or other issues,” said Mr Bowland. “We’re looking at plumbing in walls where you can’t get a scope up a wall. We can get it there.

“The technology can be used in a nuclear reactor, in turbines in power stations, on North Sea oil rigs and down mines.” He said there are huge opportunities for the technology and the group has assigned two design engineers with the task of looking at new industrial applications. They include senior design engineer David Main, who is one of the team that developed Pretzel-Flex, a pretzel-shaped device that can reposition large organs, such as the liver, during keyhole surgery

[bashor] 15/9/2018 10:05

Yes agreed, I guess the volatility of recent years doesn’t help, I’d like to set the spread down too

[bjfanc] 15/9/2018 07:17

Quoted spread is laughable, at the moment.

[bashor] 14/9/2018 22:48

Slightly odd trading day, must be an overhang as all buys... Humm?

[jmf69] 14/9/2018 09:23

Yep between this and BIOM I'm invested pretty heavy.Hopefully the next 12 to 18 months should reward the risk.